Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron Jun 9, 2026 08:01AM
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)  Jun 9, 2026 08:00AM
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis Jun 1, 2026 08:00AM
Nasus Pharma to Participate in Upcoming Investor Conferences May 1, 2026 09:13AM
Nasus Pharma to Participate in Upcoming Investor Conferences May 1, 2026 09:13AM


Apr 21, 2026 03:00PM RedChip's Biotech Virtual Investor Conference Replays Now Available
Apr 7, 2026 11:00AM RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
Mar 25, 2026 09:00AM Nasus Pharma advances epinephrine nasal spray toward pivotal trial
Mar 25, 2026 09:00AM Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Mar 16, 2026 07:30AM Nasus Pharma reports faster epinephrine delivery in phase 2 study
Mar 16, 2026 07:30AM Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Thera
Mar 9, 2026 08:30AM Nasus Pharma to present NS002 intranasal epinephrine study results
Mar 9, 2026 08:30AM Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
Mar 9, 2026 08:00AM Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
Mar 9, 2026 08:00AM Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
Feb 20, 2026 08:00AM Nasus Pharma to Participate in Upcoming Investor Conferences
Feb 17, 2026 08:00AM Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
Feb 13, 2026 08:00AM Nasus Pharma completes $15 million private placement
Feb 13, 2026 08:00AM Nasus Pharma Announces Closing of $15.0 Million Private Placement
Feb 10, 2026 11:03PM Nasus Pharma prices $15 million private placement for drug development
Feb 10, 2026 11:03PM Nasus Pharma Announces Pricing of $15.0 Million Private Placement
Jan 20, 2026 08:00AM Nasus Pharma reports faster epinephrine absorption in phase 2 trial
Jan 20, 2026 08:00AM Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Dec 22, 2025 08:00AM Nasus Pharma outlines 2026 clinical milestones for NS002 epinephrine
Dec 22, 2025 08:00AM Nasus Pharma CEO Issues 2025 Letter to Shareholders
Nov 20, 2025 08:15AM Nasus Pharma names Eyal Rubin as CFO and executive vice president
Nov 20, 2025 08:15AM Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
Nov 18, 2025 08:00AM Nasus Pharma begins Phase 2 study of intranasal epinephrine treatment
Nov 18, 2025 08:00AM Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Nov 6, 2025 08:00AM Nasus Pharma receives Health Canada approval to start NS002 phase 2 study
Nov 6, 2025 08:00AM Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Oct 8, 2025 08:04AM Nasus Pharma expands Aptar partnership for NS002 epinephrine development
Oct 8, 2025 08:04AM Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program